Cevostamab Efficacy in Triple-Class Refractory RRMM Patients

This technical report presents initial results from the Phase I/II CAMMA 2 study evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who are triple-class refractory and have previously received a BCMA-targeted agent. The study involved a cohort of patients who were administered cevostamab through intravenous infusions, with a focus on evaluating the overall response rate (ORR) and safety profile. Key findings indicate that cevostamab demonstrated high response rates, with an ORR of 73% in patients who had prior CAR T-cell therapy and 60% in those who had received prior antibody-drug conjugates (ADCs). Adverse events were consistent with the known safety profile of cevostamab, primarily low-grade cytokine release syndrome (CRS) occurring mainly during the first cycle. The report also discusses the expression of FcRH5 on myeloma cells, suggesting a rationale for the use of cevostamab in this patient population. Overall, the findings indicate a promising potential for cevostamab in managing RRMM patients who have progressed on previous therapies.